Syed Sattar, MD
Psychiatry · Omaha, NENPI 1942314604
Payments from drug & device makers
Across 974 payments — averaging $16.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Otsuka America Pharmaceutical, Inc.$2K
- Alkermes, Inc.$2K
- Neurocrine Biosciences, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Vanda Pharmaceuticals Inc.$1K
- plus $6K from 23 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 184 | $2,932 |
| Otsuka America Pharmaceutical, Inc. | 124 | $1,906 |
| Alkermes, Inc. | 111 | $1,720 |
| Neurocrine Biosciences, Inc. | 85 | $1,279 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 69 | $1,189 |
| Vanda Pharmaceuticals Inc. | 54 | $1,120 |
| Johnson & Johnson | 65 | $1,112 |
| Teva Pharmaceuticals USA, Inc. | 72 | $1,083 |
| Sunovion Pharmaceuticals Inc. | 64 | $952 |
| E.r. Squibb & Sons, L.L.C. | 31 | $473 |
| Lundbeck LLC | 28 | $472 |
| Indivior Inc. | 14 | $288 |
| Harmony Biosciences LLC | 7 | $154 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $136 |
| Almatica Pharma LLC | 7 | $128 |
| Axsome Therapeutics, Inc. | 7 | $118 |
| Jazz Pharmaceuticals Inc. | 7 | $104 |
| Avanir Pharmaceuticals, Inc. | 7 | $93 |
| Eisai Inc. | 5 | $69 |
| Bausch Health US, LLC | 3 | $60 |
| Gilead | 3 | $58 |
| Idorsia Pharmaceuticals US Inc | 4 | $56 |
| Merck | 4 | $53 |
| Noven Therapeutics, LLC | 3 | $42 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| Biohaven Pharmaceuticals, Inc. | 1 | $26 |
| Neuronetics, Inc. | 2 | $21 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $13 |
How this compares
$15,706 in reported general payments places this provider in the 90th percentile of 160 psychiatry providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Omaha
- Vithyalakshmi SelvarajOmaha$1.5M
- Sarit HovavOmaha$307K
- Mary Jo HaniganOmaha$119K
- Yon ChongOmaha$59K
- Sriram RamaswamyOmaha$31K
- Michael SedlacekOmaha$15K
- Elizabeth FitzpatrickOmaha$10K
- Syed QadriOmaha$9K
- Praveen FernandesOmaha$5K
- Natalie BakerOmaha$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.